Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PBF-999 in Healthy Volunteers
NCT02208934Phase 1Completed
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PBF-999 in Huntington's disease (HD) (5 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events. Started Sep 2014; status: completed.
02
Drugs
PBF-999
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02208934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208934.